Evidence map›Paper›PMID 38315532›Full record

ReviewBlood transfusion = Trasfusione del sangue2025

Noninvasive fetal blood group antigen genotyping.

Frederik B Clausen, C Ellen van der Schoot

Abstract readReview
In one paragraph

Review in Blood transfusion = Trasfusione del sangue, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Frederik B ClausenLaboratory of Blood Genetics, Department of Clinical Immunology, Copenhagen University HospitalCopenhagen, Denmark.
C Ellen van der SchootDepartment of Experimental Immunohematology, Sanquin Research, Amsterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Noninvasive fetal blood group antigen genotyping serves as a diagnostic tool to predict the risk of hemolytic disease of the fetus and newborn in pregnancies of immunized women. In addition, fetal RHD genotyping is used as an antenatal screening to guide targeted use of immunoglobulin prophylaxis in non-immunized RhD negative, pregnant women. Based on testing of cell-free DNA extracted from maternal plasma, these noninvasive assays demonstrate high performance accuracies. Consequently, noninvasive fetal blood group antigen genotyping has become standard care in transfusion medicine.

Indexed as

Blood Group AntigensCell-Free Nucleic AcidsErythroblastosis, FetalFetal BloodGenotyping TechniquesPrenatal DiagnosisRh-Hr Blood-Group SystemBlood Grouping and CrossmatchingFemaleGenotypeHumansInfant, NewbornPregnancyBlood Group AntigensCell-Free Nucleic AcidsRh-Hr Blood-Group SystemRho(D) antigen

Identifiers

PMID38315532
PMCPMC11925261

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.